2012•Rinsho ShinkeigakuOpen access

Multifocal motor neuropathy: Current review of epidemiology and treatment

Naoko Matsui

Open full text 10 citations

Abstract

The diagnosis of multifocal motor neuropathy (MMN) is often missed because MMN disguises itself as a motor neuron disease and is considered relatively rare. Detailed epidemiological studies of MMN have not been undertaken. We therefore conducted a nationwide survey of MMN in comparison with amyotrophic lateral sclerosis (ALS). This retrospective study examined 47 patients with MMN and 1,051 patients with ALS from major neuromuscular centers in Japan from 2005 to 2009. MMN had a younger age of onset and was more common in males than ALS. The ratio of MMN to ALS patients (0-0.10) varied among the centers, but mostly converged to 0.05. The prevalence was estimated to be 0.3 cases for MMN and 6.63 cases for ALS per 100,000 persons. Twenty-five MMN patients (54.2%) showed conduction block. Thirty-four (75%) of 45 MMN patients received intravenous immunoglobulin exhibited a favorable outcome. It is expected that more sensitive indicators of conduction block or focal demyelinating lesions than currently available MMN diagnostic criteria would further increase the ratio of MMN to ALS patients and the total number of MMN patients who can benefit from treatment. MMN is by no means a rare disorder but should be accurately diagnosed in all neuromuscular centers.

Open-access reader

About this research paper

What this paper is about

The diagnosis of multifocal motor neuropathy (MMN) is often missed because MMN disguises itself as a motor neuron disease and is considered relatively rare. Detailed epidemiological studies of MMN have not been undertaken. We therefore conducted a nationwide survey of MMN in comparison with amyotrophic lateral sclerosis (ALS). This retrospective study examined 47 patients with MMN and 1,051 patients with ALS from major neuromuscular centers in Japan from 2005 to 2009. MMN had a younger age of onset and was more common in males than ALS. The ratio of MMN to ALS patients (0-0.10) varied among the centers, but mostly converged to 0.05. The prevalence was estimated to be 0.3 cases for MMN and 6.63 cases for ALS per 100,000 persons. Twenty-five MMN patients (54.2%) showed conduction block. Thirty-four (75%) of 45 MMN patients received intravenous immunoglobulin exhibited a favorable outcome. It is expected that more sensitive indicators of conduction block or focal demyelinating lesions than currently available MMN diagnostic criteria would further increase the ratio of MMN to ALS patients and the total number of MMN patients who can benefit from treatment. MMN is by no means a rare disorder but should be accurately diagnosed in all neuromuscular centers.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The diagnosis of multifocal motor neuropathy (MMN) is often missed because MMN disguises itself as a motor neuron disease and is considered relatively rare. Detailed epidemiological studies of MMN have not been undertaken. We therefore conducted a nationwide survey of MMN in comparison with amyotrophic lateral sclerosis (ALS). This retrospective study examined 47 patients with MMN and 1,051 patients with ALS from major neuromuscular centers in Japan from 2005 to 2009. MMN had a younger age of onset and was more common in males than ALS. The ratio of MMN to ALS patients (0-0.10) varied among the centers, but mostly converged to 0.05. The prevalence was estimated to be 0.3 cases for MMN and 6.63 cases for ALS per 100,000 persons. Twenty-five MMN patients (54.2%) showed conduction block. Thirty-four (75%) of 45 MMN patients received intravenous immunoglobulin exhibited a favorable outcome. It is expected that more sensitive indicators of conduction block or focal demyelinating lesions than currently available MMN diagnostic criteria would further increase the ratio of MMN to ALS patients and the total number of MMN patients who can benefit from treatment. MMN is by no means a rare disorder but should be accurately diagnosed in all neuromuscular centers.

Key concepts: Mismatch negativity, Multifocal motor neuropathy, Medicine, Amyotrophic lateral sclerosis, Audiology, Epidemiology, Upper motor neuron, Retrospective cohort study

Related papers

Back to paper searchBrowse research topicsOriginal source
Multifocal motor neuropathy: Current review of epidemiology and treatment — Research Paper | ScholarLens